Patents by Inventor Paul Vincent Rucker

Paul Vincent Rucker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE
    Publication number: 20220127247
    Abstract: The invention relates to heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.
    Type: Application
    Filed: February 4, 2020
    Publication date: April 28, 2022
    Inventors: Mihai AZIMIOARA, Bei CHEN, Robert EPPLE, James Paul LAJINESS, Casey Jacob Nelson MATHISON, Juliet NABAKKA, Victor Ivanovich NIKULIN, Sejal PATEL, Dean Paul PHILLIPS, Paul Vincent RUCKER, Andrew VALIERE, Baogen WU, Shanshan YAN, Xuefeng ZHU
  • COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS
    Publication number: 20210253534
    Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
    Type: Application
    Filed: April 21, 2021
    Publication date: August 19, 2021
    Inventors: Donatella CHIANELLI, Runyan LI, Valentina MOLTENI, John NELSON, Jason Thomas ROLAND, Paul Vincent RUCKER, David Charles TULLY, Xiaoyang WANG, Liladhar Murlidhar WAYKOLE, Yubo ZHANG, Bo ZHOU
  • Compositions and methods for modulating farnesoid X receptors
    Patent number: 11021446
    Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: June 1, 2021
    Assignee: Novartis AG
    Inventors: Donatella Chianelli, Runyan Li, Valentina Molteni, John Nelson, Jason Thomas Roland, Paul Vincent Rucker, David Charles Tully, Xiaoyang Wang, Liladhar Murlidhar Waykole, Yubo Zhang, Bo Zhou
  • COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS
    Publication number: 20200247757
    Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
    Type: Application
    Filed: April 21, 2020
    Publication date: August 6, 2020
    Inventors: Donatella CHIANELLI, Runyan LI, Valentina MOLTENI, John NELSON, Jason Thomas ROLAND, Paul Vincent RUCKER, David Charles TULLY, Xiaoyang WANG, Liladhar Murlidhar WAYKOLE, Yubo ZHANG, Bo ZHOU
  • Compositions and methods for modulating farnesoid X receptors
    Patent number: 10683271
    Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: June 16, 2020
    Assignee: Novartis AG
    Inventors: Donatella Chianelli, Xiaodong Liu, Valentina Molteni, John Nelson, Jason Thomas Roland, Paul Vincent Rucker, David Charles Tully
  • Fused tricyclic pyrazole derivatives useful for farnesoid X receptors
    Patent number: 10351576
    Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: July 16, 2019
    Assignee: Novartis AG
    Inventors: Donatella Chianelli, Xiaodong Liu, Valentina Molteni, John Nelson, Jason Roland, Paul Vincent Rucker, David Charles Tully
  • COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS
    Publication number: 20190062283
    Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
    Type: Application
    Filed: August 7, 2018
    Publication date: February 28, 2019
    Inventors: Donatella CHIANELLI, Runyan LI, Valentina Molteni, John Nelson, Jason Thomas Roland, Paul Vincent Rucker, David Charles Tully, Xiaoyang WANG, Liladhar Murlidhar WAYKOLE, Yubo ZHANG, Bo ZHOU
  • FUSED TRICYCLIC PYRAZOLE DERIVATIVES USEFUL FOR FARNESOID X RECEPTORS
    Publication number: 20180298018
    Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
    Type: Application
    Filed: April 29, 2016
    Publication date: October 18, 2018
    Inventors: Donatella CHIANELLI, Xiaodong LIU, Valentina MOLTENI, John NELSON, Jason ROLAND, Paul Vincent RUCKER, David Charles TULLY
  • Compositions and methods for modulating farnesoid X receptors
    Patent number: 10077240
    Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: September 18, 2018
    Assignee: Novartis AG
    Inventors: Donatella Chianelli, Valentina Molteni, John Nelson, Jason Thomas Roland, Paul Vincent Rucker, David Charles Tully
  • COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS
    Publication number: 20170275256
    Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
    Type: Application
    Filed: May 18, 2017
    Publication date: September 28, 2017
    Inventors: Donatella CHIANELLI, Valentina MOLTENI, John NELSON, Jason Thomas ROLAND, Paul Vincent RUCKER, David Charles TULLY
  • Compositions and methods for modulating farnesoid X receptors
    Patent number: 9682939
    Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
    Type: Grant
    Filed: November 4, 2014
    Date of Patent: June 20, 2017
    Assignee: Novartis AG
    Inventors: Donatella Chianelli, Xiaodong Liu, Valentina Molteni, John Nelson, Jason Thomas Roland, Paul Vincent Rucker, David Charles Tully
  • Compositions and methods for modulating FXR
    Patent number: 9150568
    Abstract: The present invention relates to compounds of Formula (I), a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesiod X receptors (FXR).
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: October 6, 2015
    Assignee: NOVARTIS AG
    Inventors: David C. Tully, Paul Vincent Rucker, Phillip B. Alper, Daniel Mutnick, Donatella Chianelli
  • COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS
    Publication number: 20150051206
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFR?, PDGFR?) kinases.
    Type: Application
    Filed: August 29, 2012
    Publication date: February 19, 2015
    Applicant: IRM LLC
    Inventors: Jon Loren, Xiaolin Li, Xiaodong Liu, Valentina Molteni, Juliet Nabakka, Bao Nguyen, Hank Michael James Petrassi, Vince Yeh, Paul Vincent Rucker
  • Tricyclic compounds, compositions, and methods
    Patent number: 8901310
    Abstract: The present invention is directed to compounds of Formula I: or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: December 2, 2014
    Assignee: Pfizer Inc.
    Inventors: Paul Vincent Rucker, Jeffery S. Snyder
  • Tricyclic Compounds, Compositions, And Methods
    Publication number: 20140316139
    Abstract: The present invention is directed to compounds of Formula I: or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity.
    Type: Application
    Filed: July 1, 2014
    Publication date: October 23, 2014
    Inventors: Paul Vincent RUCKER, Jeffery S. SNYDER
  • COMPOSITIONS AND METHODS FOR MODULATING FXR
    Publication number: 20130331349
    Abstract: The present invention relates to compounds of Formula (I), a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesiod X receptors (FXR).
    Type: Application
    Filed: November 30, 2011
    Publication date: December 12, 2013
    Inventors: David C. Tully, Paul Vincent Rucker, Phillip B. Alper, Daniel Mutnick, Donatella Chianelli
  • Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
    Patent number: 8507488
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly Ros, KDR, FMS, C-FMS, FLT3, c-Kit, JAK2, JAK3, Aurora, PDGFR, Lck, TrkA, TrkB, TrkC, IGF-IR, ALK4, ALK5 and ALK or combinations thereof.
    Type: Grant
    Filed: May 7, 2009
    Date of Patent: August 13, 2013
    Assignee: IRM LLC
    Inventors: Pamela A. Albaugh, Ha-Soon Choi, Gregory Chopiuk, Yi Fan, Paul Vincent Rucker, Zhicheng Wang
  • FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS
    Publication number: 20110166133
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly Ros, KDR, FMS, C-FMS, FLT3, c-Kit, JAK2, JAK3, Aurora, PDGFR, Lck, TrkA, TrkB, TrkC, IGF-IR, ALK4, ALK5 and ALK or combinations thereof.
    Type: Application
    Filed: May 7, 2009
    Publication date: July 7, 2011
    Applicant: IRM LLC
    Inventors: Pamela A. Albaugh, Ha-Soon Choi, Gregory Chopiuk, Yi Fan, Paul Vincent Rucker, Zhicheng Wang